The report provides an in-depth assessment of the MDD market including disease overview, epidemiology, disease management, competitive assessment, unmet needs, R&D strategies, current and future players, and market outlook.
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide, and is characterized by single or recurrent major depressive episodes (MDEs). Episodes of depression can be classified as mild, moderate, or severe, based on the number and severity of symptoms experienced. In addition, a subset of patients in each severity can be classified as being treatment-resistant, typically when patients do not respond to at least two antidepressant treatments. MDD is a recurrent disorder, and for many patients, an initial episode of depression evolves into a recurrent and debilitating chronic illness with significant impairments in psychosocial functioning.
The management of MDD involves acute, short-term therapy from when patients are initially provided treatment until remission of their depressive symptoms, and long-term maintenance treatment aimed at preventing the recurrence of symptoms with an attempt to enable a full, lasting, and functional recovery. There is a wide range of antidepressants available to treat MDD, as well as a variety of other drugs that can be added on to boost treatment with antidepressants.
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide, and is characterized by single or recurrent major depressive episodes (MDEs). Episodes of depression can be classified as mild, moderate, or severe, based on the number and severity of symptoms experienced. In addition, a subset of patients in each severity can be classified as being treatment-resistant, typically when patients do not respond to at least two antidepressant treatments. MDD is a recurrent disorder, and for many patients, an initial episode of depression evolves into a recurrent and debilitating chronic illness with significant impairments in psychosocial functioning.
The management of MDD involves acute, short-term therapy from when patients are initially provided treatment until remission of their depressive symptoms, and long-term maintenance treatment aimed at preventing the recurrence of symptoms with an attempt to enable a full, lasting, and functional recovery. There is a wide range of antidepressants available to treat MDD, as well as a variety of other drugs that can be added on to boost treatment with antidepressants.
Key Highlights
- Forecast includes the 8 major markets (8MM)
- Forecast covers the period 2019-2029
Scope
- Overview of major depressive disorder (MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized MDD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three adult patient segments (mild, moderate, and severe) from 2019 to 2029.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MDD therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the MS therapeutics market.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global MDD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MDD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1. Major Depressive Disorder: Executive Summary - Updated Nov 2023, based on events up to Oct 31, 20232. Introduction - Updated Nov 2023, based on events up to Oct 31, 2023
3. Disease Overview - Updated Nov 2023, based on events up to Oct 31, 2023
4. Epidemiology
5. Disease Management - Updated Nov 2023, based on events up to Oct 31, 2023
6. Competitive Assessment - Updated Nov 2023, based on events up to Oct 31, 2023
7. Unmet Needs and Opportunity Assessment - Updated Nov 2023, based on events up to Oct 31, 2023
8. R&D Strategies - Updated Nov 2023, based on events up to Oct 31, 2023
9. Pipeline Assessment - Updated Nov 2023, based on events up to Oct 31, 2023
10. Pipeline Valuation Analysis - Updated Nov 2023, based on events up to Oct 31, 2023
11. Current and Future Players - Updated Nov 2023, based on events up to Oct 31, 2023
12. Market Outlook - Updated Nov 2023, based on events up to Oct 31, 2023
13. Appendix - Updated Apr 2023, based on events up to Apr 13, 2023
List of Tables
Table 1: MDD: Key metrics in the 8MM
Table 2: DSM-V criteria of major depressive episode
Table 3: ICD-10 criteria of major depressive episode
Table 4: Subtypes of major depressive episode
Table 5: Risk factors and comorbidities for MDD
Table 6: Treatment guidelines for MDD
Table 7: MDD market - global drivers and barriers, 2019-29
Table 8: Key events impacting sales for MDD in the US, 2019-29
Table 9: MDD market - drivers and barriers in the US, 2019-29
Table 10: Key events impacting sales for MDD in the 5EU, 2019-29
Table 11: MDD market - drivers and barriers in the 5EU, 2019-29
Table 12: Key events impacting sales for MDD in Japan, 2019-29
Table 13: MDD market - drivers and barriers in Japan, 2019-29
Table 14: Key events impacting sales for MDD in Canada, 2019-29
Table 15: MDD market - drivers and barriers in Canada, 2019-29
Table 16: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: Global sales forecast by country for MDD in 2019 and 2029
Figure 2: Analysis of the company portfolio gap in MDD during the forecast period
Figure 3: Overview of targets of antidepressant action on noradrenergic and serotonergic neurons
Figure 4: 8MM, total prevalence of MDD (%), men and women, ages ≥18 years, 2019
Figure 5: 8MM, sources used and not used to forecast the 12-month total prevalent cases of MDD
Figure 6: 8MM, sources used to forecast the 12-month total prevalent cases of MDD, by severity
Figure 7: 8MM, 12-month total prevalent cases of MDD, both sexes, ages ≥18 years, 2019
Figure 8: 8MM 12-month total prevalent cases of MDD, by age, N, both sexes, 2019
Figure 9: 8MM, 12-month total prevalent cases of MDD, by sex, N, ages ≥18 years, 2019
Figure 10: 8MM, total prevalent cases of MDD by severity, N, both sexes, ages ≥18 years, 2019
Figure 11: Disease management model for MDD
Figure 12: MDD treatment algorithm
Figure 13: Unmet needs and opportunities in MDD
Figure 14: Overview of the development pipeline in MDD
Figure 15: Key late-stage trials for the promising pipeline agents that the publisher expects be licensed for MDD in the 8MM during the forecast period
Figure 16: Competitive assessment of the pipeline drug monotherapies benchmarked against SOC Lexapro (escitalopram)
Figure 17: Competitive assessment of the pipeline adjunctive therapies benchmarked against the SOC, Abilify
Figure 18: Analysis of the company portfolio gap in MDD during the forecast period
Figure 19: Global (8MM) sales forecast by country for MDD in 2019 and 2029
Figure 20: Global (8MM) sales forecast by class for MDD in 2019 and 2029
Figure 21: Sales forecast by class for MDD in the US in 2019 and 2029
Figure 22: Sales forecast by country for MDD in the 5EU in 2019 and 2029
Figure 23: Sales forecast by class for MDD in the 5EU in 20219 and 2029
Figure 24: Sales forecast by class for MDD in Japan in 2019 and 2029
Figure 25: Sales forecast by class for MDD in Canada in 2019 and 2029
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbvie
- Appotex
- Arrivo BioVentures
- AstraZeneca
- Axsome Therapeutics
- Bausch Health
- Biogen
- Bristol-Myers Squibb
- Compass Pathways
- Eli Lilly
- Fabre-Kramer Pharmaceuticals
- Gedeon Richter
- GSK
- Intra-Cellular Therapies
- Johnson & Johnson
- Laboratoires Pierre Fabre
- Lundbeck
- Meiji Holdings
- Merck
- Mochida Pharmaceutical
- Mylan
- Neumora Therapeutics
- Organon
- Otsuka
- Pfizer
- Relmada Therapeutics
- Sage Therapeutics
- Sirtsei Pharmaceuticals
- Takeda Pharmaceuticals
- Viatris
